- Published on
Infectious Disease – Anthrax
BASICS DESCRIPTION
• Anthrax is a zoonotic illness primarily affecting herbivores and infrequently infects humans. The phrase originates from the Greek word for coal and refers to the black eschar associated with the cutaneous variant of the disease. • In humans, the disease manifests predominantly in three forms: cutaneous, respiratory, and gastrointestinal. • Duration of incubation: - Dermatological condition: 3–10 days - Pulmonary disease: 3 to 5 days
Epidemiology • Anthrax is an infrequent disease in the United States. • Epidemics have been documented in relation to the importation of wool, skins, and other animal derivatives. Epidemics in humans in underdeveloped nations are associated with diseases in animals. Foodborne outbreaks have been recorded and associated with the consumption of contaminated meat. In 2001, there were 22 confirmed or suspected cases of anthrax (11 cutaneous and 11 inhalational) associated with bioterrorism in the United States. Five of these patients succumbed. Since December 2009, Scotland has reported a total of 31 instances, including 11 fatalities, of a novel variant of the disease previously characterized as "injectional."
ETIOLOGY
Bacillus anthracis is an aerobic, gram-positive, spore-forming bacterium. Endospores exhibit resistance to desiccation, radiation, and disinfectants, and can remain dormant in soil for extended periods, often for years.
risk FACTORS • In developing nations, the primary danger arises from exposure to contaminated soil or diseased animals. In urban areas, the primary risk arises from exposure to tainted skins and animal fur.
COMPREHENSIVE PREVENTION
• Vaccination of livestock is recommended in endemic regions. • Decontamination of imported skins and animal hair would mitigate danger. The anthrax vaccination is accessible to those at risk of exposure to the pathogen. These encompass military personnel, veterinarians, and individuals exposed to imported hides or animal fur.
Pathophysiology
The synthesis of two binary toxins (lethal toxin and edema toxin) is crucial for the pathogenic process.
DIAGNOSIS
Disease can present as cutaneous, respiratory, or gastrointestinal, with cutaneous being the predominant type. Meningitis may arise as a complication from bacteremic dissemination originating from any of the three principal types.
PHYSICAL EXAM
• Cutaneous disease: The characteristic lesion is a circular eschar (1–3 cm) that may initially present as an ulcerating papule. If neglected, the infection may advance to bacteremia and sepsis. Respiratory sickness typically manifests in two stages. A viral upper respiratory disease persists for 2–4 days, subsequently leading to severe fulminant pneumonitis. Nonetheless, the clinical manifestation may be uncommon, with certain patients exhibiting an absence of cough, chest pain, or irregular lung examination findings. Gastrointestinal disease typically manifests with abdominal discomfort, nausea, vomiting, and fever, and may be accompanied by hematemesis and hematochezia. • Anthrax meningoencephalitis can aggravate bacteremia and may present with a hyperacute onset, rapidly progressing to coma and death. Anthrax in injectable drug users is a serious condition characterized by soft tissue infection, tight edema, cerebral or subarachnoid bleeding, and gastrointestinal symptoms. A typical cutaneous lesion should raise suspicion of anthrax. Assessing the history of exposure to sick or deceased animals, hides, or fur can be beneficial. The diagnosis of pneumonia or gastroenteritis is challenging to ascertain due to the vague clinical manifestations. • A significant observation is that in advanced pulmonary disease, the mediastinum expands on chest X-ray. The conjunction of mediastinal enlargement, altered mental status, and raised hematocrit is 100% sensitive in differentiating inhalational anthrax from community-acquired pneumonia. • Hemorrhagic cerebrospinal fluid and gram-positive bacilli on Gram staining indicate potential meningeal involvement.
DIAGNOSTIC TESTS AND INTERPRETATION LAB • Cultures and Gram stains of vesicular lesions should identify the organism—a large, encapsulated, gram-positive rod arranged in short chains. • Blood cultures are typically positive in febrile, acutely ill patients with pulmonary or gastrointestinal conditions. • Stool cultures detect the organism in gastrointestinal disease. Chest X-ray films frequently demonstrate diffuse infiltrates and effusions. The mediastinum may exhibit widening in the later stages of the disease.
DIFFERENTIAL DIAGNOSIS • Cutaneous – Tularemia – Staphylococcus aureus – Spider bite – Burn lesion • Pulmonary – Diverse bacterial and viral infections • Gastrointestinal – Shigella – Yersinia – Campylobacter • Meningitis – Tuberculosis – Amebic meningoencephalitis – Specific viral infections: Hantavirus, dengue, Ebola
Treatment / Medication
• Naturally acquired cutaneous anthrax in individuals over 2 years of age: - Administer oral ciprofloxacin (500 mg twice day for adults and 15 mg/kg twice daily, not to exceed 500 mg for children) for a duration of 7 to 10 days. - Oral doxycycline (100 mg twice daily in adults and 2.2 mg/kg—capped at 100 mg—twice daily in children) for a duration of 7 to 10 days If susceptibility testing is accessible, administer penicillin G 6–8 million units per day intravenously, penicillin VK 500 mg four times daily, and 50 mg/kg/day in children under 12 years, or amoxicillin orally 500 mg three times daily and 45 mg/kg/day in children to finish the treatment course. – Notwithstanding the possibility of resistance and inducible resistance, an administration of penicillin for approximately 7–10 days may be adequate for the treatment of naturally acquired simple cutaneous anthrax. Levofloxacin may be suggested as an alternative choice.
• For severe cases of spontaneously occurring cutaneous anthrax: – Administer IV ciprofloxacin 400 mg twice daily and 10 mg/kg twice daily in pediatric patients – Administer IV doxycycline 100 mg twice daily in adults and 2.2 mg/kg twice daily in pediatric patients • Cutaneous anthrax associated with bioterrorism: administer oral ciprofloxacin, oral doxycycline, or oral amoxicillin at the recommended dosages for 60 days to fulfill the complete course of postexposure prophylaxis. • For inhalational anthrax, gastrointestinal anthrax, and fulminant bacteremia: – Intravenous ciprofloxacin is preferred over intravenous doxycycline. The combination regimens may consist of IV ciprofloxacin or IV doxycycline in conjunction with one or two of the following agents: imipenem, meropenem, rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, or clindamycin. • Employ a minimum of one drug with enough CNS penetration to address the potential for subclinical meningitis. Some experts recommend the inclusion of clindamycin to suppress endotoxin formation. A human IgG1λ monoclonal antibody targeting a component of the anthrax toxin (raxibacumab) enhanced survival in rabbits and monkeys afflicted with symptomatic inhalational anthrax (IA).
CONTINUED MANAGEMENT SUBSEQUENT SUGGESTIONS
Patients should be monitored for signs of disease recurrence following treatment.
COMPLICATIONS • Pulmonary and gastrointestinal disorders are typically lethal. • Cutaneous disease frequently results in scarring at the site of the eschar.
BASICS DESCRIPTION
• Anthrax is a zoonotic illness primarily affecting herbivores and infrequently infects humans. The phrase originates from the Greek word for coal and refers to the black eschar associated with the cutaneous variant of the disease. • In humans, the disease manifests predominantly in three forms: cutaneous, respiratory, and gastrointestinal. • Duration of incubation: - Dermatological condition: 3–10 days - Pulmonary disease: 3 to 5 days
Epidemiology • Anthrax is an infrequent disease in the United States. • Epidemics have been documented in relation to the importation of wool, skins, and other animal derivatives. Epidemics in humans in underdeveloped nations are associated with diseases in animals. Foodborne outbreaks have been recorded and associated with the consumption of contaminated meat. In 2001, there were 22 confirmed or suspected cases of anthrax (11 cutaneous and 11 inhalational) associated with bioterrorism in the United States. Five of these patients succumbed. Since December 2009, Scotland has reported a total of 31 instances, including 11 fatalities, of a novel variant of the disease previously characterized as "injectional."
ETIOLOGY
Bacillus anthracis is an aerobic, gram-positive, spore-forming bacterium. Endospores exhibit resistance to desiccation, radiation, and disinfectants, and can remain dormant in soil for extended periods, often for years.
risk FACTORS • In developing nations, the primary danger arises from exposure to contaminated soil or diseased animals. In urban areas, the primary risk arises from exposure to tainted skins and animal fur.
COMPREHENSIVE PREVENTION
• Vaccination of livestock is recommended in endemic regions. • Decontamination of imported skins and animal hair would mitigate danger. The anthrax vaccination is accessible to those at risk of exposure to the pathogen. These encompass military personnel, veterinarians, and individuals exposed to imported hides or animal fur.
Pathophysiology
The synthesis of two binary toxins (lethal toxin and edema toxin) is crucial for the pathogenic process.
DIAGNOSIS
Disease can present as cutaneous, respiratory, or gastrointestinal, with cutaneous being the predominant type. Meningitis may arise as a complication from bacteremic dissemination originating from any of the three principal types.
PHYSICAL EXAM
• Cutaneous disease: The characteristic lesion is a circular eschar (1–3 cm) that may initially present as an ulcerating papule. If neglected, the infection may advance to bacteremia and sepsis. Respiratory sickness typically manifests in two stages. A viral upper respiratory disease persists for 2–4 days, subsequently leading to severe fulminant pneumonitis. Nonetheless, the clinical manifestation may be uncommon, with certain patients exhibiting an absence of cough, chest pain, or irregular lung examination findings. Gastrointestinal disease typically manifests with abdominal discomfort, nausea, vomiting, and fever, and may be accompanied by hematemesis and hematochezia. • Anthrax meningoencephalitis can aggravate bacteremia and may present with a hyperacute onset, rapidly progressing to coma and death. Anthrax in injectable drug users is a serious condition characterized by soft tissue infection, tight edema, cerebral or subarachnoid bleeding, and gastrointestinal symptoms. A typical cutaneous lesion should raise suspicion of anthrax. Assessing the history of exposure to sick or deceased animals, hides, or fur can be beneficial. The diagnosis of pneumonia or gastroenteritis is challenging to ascertain due to the vague clinical manifestations. • A significant observation is that in advanced pulmonary disease, the mediastinum expands on chest X-ray. The conjunction of mediastinal enlargement, altered mental status, and raised hematocrit is 100% sensitive in differentiating inhalational anthrax from community-acquired pneumonia. • Hemorrhagic cerebrospinal fluid and gram-positive bacilli on Gram staining indicate potential meningeal involvement.
DIAGNOSTIC TESTS AND INTERPRETATION LAB • Cultures and Gram stains of vesicular lesions should identify the organism—a large, encapsulated, gram-positive rod arranged in short chains. • Blood cultures are typically positive in febrile, acutely ill patients with pulmonary or gastrointestinal conditions. • Stool cultures detect the organism in gastrointestinal disease. Chest X-ray films frequently demonstrate diffuse infiltrates and effusions. The mediastinum may exhibit widening in the later stages of the disease.
DIFFERENTIAL DIAGNOSIS • Cutaneous – Tularemia – Staphylococcus aureus – Spider bite – Burn lesion • Pulmonary – Diverse bacterial and viral infections • Gastrointestinal – Shigella – Yersinia – Campylobacter • Meningitis – Tuberculosis – Amebic meningoencephalitis – Specific viral infections: Hantavirus, dengue, Ebola
Treatment / Medication
• Naturally acquired cutaneous anthrax in individuals over 2 years of age: - Administer oral ciprofloxacin (500 mg twice day for adults and 15 mg/kg twice daily, not to exceed 500 mg for children) for a duration of 7 to 10 days. - Oral doxycycline (100 mg twice daily in adults and 2.2 mg/kg—capped at 100 mg—twice daily in children) for a duration of 7 to 10 days If susceptibility testing is accessible, administer penicillin G 6–8 million units per day intravenously, penicillin VK 500 mg four times daily, and 50 mg/kg/day in children under 12 years, or amoxicillin orally 500 mg three times daily and 45 mg/kg/day in children to finish the treatment course. – Notwithstanding the possibility of resistance and inducible resistance, an administration of penicillin for approximately 7–10 days may be adequate for the treatment of naturally acquired simple cutaneous anthrax. Levofloxacin may be suggested as an alternative choice.
• For severe cases of spontaneously occurring cutaneous anthrax: – Administer IV ciprofloxacin 400 mg twice daily and 10 mg/kg twice daily in pediatric patients – Administer IV doxycycline 100 mg twice daily in adults and 2.2 mg/kg twice daily in pediatric patients • Cutaneous anthrax associated with bioterrorism: administer oral ciprofloxacin, oral doxycycline, or oral amoxicillin at the recommended dosages for 60 days to fulfill the complete course of postexposure prophylaxis. • For inhalational anthrax, gastrointestinal anthrax, and fulminant bacteremia: – Intravenous ciprofloxacin is preferred over intravenous doxycycline. The combination regimens may consist of IV ciprofloxacin or IV doxycycline in conjunction with one or two of the following agents: imipenem, meropenem, rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, or clindamycin. • Employ a minimum of one drug with enough CNS penetration to address the potential for subclinical meningitis. Some experts recommend the inclusion of clindamycin to suppress endotoxin formation. A human IgG1λ monoclonal antibody targeting a component of the anthrax toxin (raxibacumab) enhanced survival in rabbits and monkeys afflicted with symptomatic inhalational anthrax (IA).
CONTINUED MANAGEMENT SUBSEQUENT SUGGESTIONS
Patients should be monitored for signs of disease recurrence following treatment.
COMPLICATIONS • Pulmonary and gastrointestinal disorders are typically lethal. • Cutaneous disease frequently results in scarring at the site of the eschar.
0 Comments
